Logo Image
News|Articles|January 6, 2026

Q4 2025 Recap: Allergy News and Updates

Fact checked by: Victoria Johnson

Q4 2025 brought key FDA approvals and phase 3 advances in HAE, peanut allergy, multi-allergen immunotherapy, and allergic fungal rhinosinusitis.

The final quarter of 2025 delivered key developments in allergy and immunology, spanning hereditary angioedema (HAE), food allergies, and allergic fungal rhinosinusitis. The US Food & Drug Administration (FDA) approved oral berotralstat, expanding treatment options for pediatric HAE. Phase 3 studies demonstrated rapid-acting HAE therapies, enhanced desensitization protocols in peanut-allergic children, and encouraging outcomes for allergic fungal rhinosinusitis.